@article{article, title  = {{Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib<i>vs</i>. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data}},

 publisher = {{Anticancer Research USA Inc.}},

 url = {{https://doi.org/10.21873/anticanres.16809 }},

 year = {{2023}},

 month = {{12}},

 author = {{MOSER SS and APTER L and SOLOMON J and CHODICK G and WOLLNER M and SIEGELMANN-DANIELI N}},

 doi = {{10.21873/anticanres.16809}},

 volume = {{44}},

 journal = {{Anticancer Research}},

 issue = {{1}},

 pages = {{257-265}},

 note = {{Accessed on 2025/02/05}}}